Filing Details

Accession Number:
0001385508-19-000090
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-04 16:04:52
Reporting Period:
2019-09-03
Accepted Time:
2019-09-04 16:04:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1385508 Opiant Pharmaceuticals Inc. OPNT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1358116 Phil Skolnick C/O Opiant Pharmaceuticals, Inc.
233 Wilshire Blvd., Suite 280
Santa Monica CA 90401
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-09-03 10,000 $9.00 10,000 No 4 M Direct
Common Stock Disposition 2019-09-03 7,506 $14.08 2,494 No 4 S Direct
Common Stock Disposition 2019-09-04 2,494 $14.37 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2019-09-03 10,000 $0.00 10,000 $9.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
80,000 2018-08-06 2027-02-06 No 4 M Direct
Footnotes
  1. The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
  2. The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
  3. This transaction was executed in multiple trades at prices ranging from $13.85 to $14.56. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This transaction was executed in multiple trades at prices ranging from $14.36 to $14.67. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.